Blocking Chloride Channels May Restore Muscle Strength Lost to Aging

Key points

• Researchers at the University of Missouri-Columbia identified a breakdown in the neuromuscular junction as a primary cause of sarcopenia, affecting nearly half of adults over 80.
• The study found that aging leads to a selective loss of NaV1.4 sodium channels at the motor endplate, impairing the muscle's ability to respond to nerve signals.
• Clinical data showed that older adults with mobility issues had a 250% increase in electrophysiological jitter and impulse blocking in up to 35% of motor endplates.
• In animal models, oral administration of small-molecule inhibitors for the ClC-1 chloride channel restored muscle force and voluntary grip strength, reversing over half of the age-related deficit.
• The lead researcher, W. David Arnold, is collaborating with Danish firm NMD Pharma to test the drug ignaseclant, which has shown promise in treating other neuromuscular disorders.

Background

This finding builds on earlier coverage from September 2026, which highlighted the identification of nerve-muscle communication breakdowns as a key driver of age-related weakness. It also follows recent research into other aging interventions, such as the AI-designed drug rentosertib, which showed preliminary results in slowing biological aging markers in lung disease patients.

How outlets are covering it

Nautilus and ScienceDaily emphasize the potential for a future pharmaceutical treatment, highlighting the collaboration with NMD Pharma and the optimism surrounding the drug ignaseclant. The European Medical Journal provides a more technical clinical perspective, detailing the specific electrophysiological evidence, such as the 250% increase in jitter, and noting that the strength gains in animal models reverted upon treatment cessation. Futurity.org focuses on the broader implication for maintaining muscle strength in older adults, framing the discovery as a shift away from focusing solely on muscle mass loss to addressing neural interface failures.

Why it matters

Sarcopenia is a major cause of functional disability and fall risk in older adults. If this approach proves effective in human trials, it could offer a non-invasive way to preserve mobility and independence, potentially reducing the burden on healthcare systems and improving quality of life for the aging population.

What to watch

The next step is to determine if the ClC-1 inhibition approach can be safely and effectively tested in older adults with sarcopenia. Arnold has presented findings from a trial of ignaseclant for Charcot-Marie-Tooth disease, suggesting a pathway for repurposing the drug for age-related weakness.